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Coronary Microvascular Dysfunction in
Systemic Lupus Erythematosus Identiﬁed by
CMR Imaging*
Dudley J. Pennell, MD, Niall G. Keenan, MD
London, United KingdomSystemic lupus erythematosus (SLE) is a multisys-
tem, autoimmune, connective tissue disorder and is
one of the strongest known risk factors for athero-
sclerosis and coronary artery disease (CAD) (1).
The range of cardiovascular disease in SLE includes
atherosclerosis, vascular inflammation, Raynaud’s
phenomenon, endothelial dysfunction, and a pro-
coagulant tendency associated with antiphospho-
lipid antibodies. It was first noted in 1976 that there
See page 27
is a bimodal pattern of death in SLE. An early peak
(within the first year of diagnosis) was related to
nephritis and sepsis. A later peak (at around 8 years
after diagnosis) was related to premature myocardial
infarction (2). The incidence of coronary artery
disease (CAD) is over 7  greater than in healthy
controls, even after matching for cardiovascular risk
factors, with a relative risk of death from myocardial
infarction of 17 (3). In women between 35 and 44
years of age with SLE, the incidence of myocardial
infarction is more than 50  greater than in the
Framingham dataset (4). The degree of SLE dis-
ease activity in the previous year correlates with
index events of CAD (5), consistent with the
paradigm of atherosclerosis as a disease of vascular
inflammation (6).
Patients with SLE frequently report chest pain.
As in the non-SLE population, there is a wide
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often involving invasive angiography, is frequently
performed because of the high incidence of CAD.
When this is normal, an alternative diagnosis, such
as pleuritis or musculoskeletal chest pain, may be
made. Some of these patients may have cardiac
syndrome X (CSX) (7), which is defined as anginal
chest pain, an exercise test that is positive for
ischemia, but normal coronary angiography (8).
Cardiac magnetic resonance (CMR) demonstrates
that 90% of CSX patients have myocardial perfu-
sion abnormalities by stress CMR, indicating that
CSX is associated with coronary microvascular dys-
function (9). CMR is a well-established technique
for myocardial perfusion imaging. It offers superior
spatial resolution to single-photon emission com-
puted tomography without exposing the patient to
ionizing radiation. There is little previous literature
on CSX and coronary microvascular dysfunction in
patients with SLE.
The paper by Ishimori et al. (10) in this issue of
iJACC describes the use of stress CMR perfusion in
a cohort of 20 SLE patients with chest pain and no
obstructive CAD on coronary computed tomogra-
phy angiography (CTA). The authors’ hypothesis is
that “chest pain in SLE patients without obstructive
CAD is due to myocardial ischemia potentially due
to microvascular coronary dysfunction.” Perfusion
abnormalities were identified in 44% of patients
compared with 0% of 10 healthy control patients.
This is an important finding because it sheds
further light on both the assessment and diagnosis
of chest pain in this sometimes challenging cohort
and on microvascular coronary disease in SLE. The
number of patients is typical for an imaging study in
this area. The gadolinium adenosine-stress first-
pass perfusion CMR technique used is the normal
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35equence in routine clinical use. Qualitative and
uantitative analysis was performed, and patients
ith established atherosclerosis were excluded.
However, some caveats are needed for the appli-
ability of these results. By design, all subjects were
emale. This was a relatively healthy SLE popula-
ion, with a low to moderate level of disease activity,
nd, in particular, there were relatively few smokers.
his may explain the coronary CTA results in
hich only 1 patient had a coronary artery calcium
core 0 and only 2 patients had any coronary
rtery plaque at all. This is in contrast to other
tudies that show a much higher prevalence of
AD. For example, a computed tomography study
n 65 SLE patients with no history of CAD found
oronary artery calcification in 31%, with a mean
oronary artery calcium score of 68.9 (11). Like-
ise, a single-photon emission computed tomogra-
hy study showed myocardial perfusion abnormal-
ties in 35% of women with SLE with no history of
AD (12). Hence, no patient had evidence of
yocardial scarring in the late phase after gadolin-
um contrast, which differs from our experience in
he inflammatory arthritides (13).
Importantly for a study of chest pain, the pa-
ients’ symptomatology is not clearly outlined.
ome patients appear to have had anginal chest
ain, whereas others had less typical angina chest
ain. Although all patients underwent coronary
TA, no patient had an exercise test; therefore, this
as a study of female SLE patients with typical and
typical anginal chest pain, which is not identical to
he strict diagnosis of CSX. This might explain why
nly 44% of patients had myocardial perfusion
efects, half the prevalence previously reported inal. Age-specific incidence rates of
myocardial infarction and angina in
drome X. Int J C
1063–9.Recent work using positron emission tomogra-
hy demonstrated reduced coronary flow reserve in
LE patients without significant CAD or tradi-
ional risk factors for CAD. This marker of coro-
ary microvascular dysfunction may be abnormal
ue to prolonged vascular inflammation in SLE.
nterestingly, in 28% of their patients, these authors
oted ischemic electrocardiographic changes with
denosine stress, similar to CSX (14). A study of
oung SLE patients with no history or other risk
actors for CAD showed that coronary flow reserve
s assessed by transthoracic echocardiography was
ignificantly reduced compared with healthy con-
rols (15). This confirms in the coronary circulation
hat has already been demonstrated in the brachial
rtery, that SLE patients have evidence of endothe-
ial dysfunction (16). CSX is associated with endo-
helial dysfunction (17), and symptoms, exercise
olerance, and endothelial function in CSX have
een significantly improved with statin therapy
18). The current study by Ishimori et al. (10)
hows that this is relevant in SLE, given that it has
lready been suggested that SLE should be re-
arded as a coronary heart disease equivalent, in
uch the same way as diabetes (19).
In summary, this study using stress CMR perfu-
ion for the first time in an SLE population shows
high burden of coronary microvascular dysfunc-
ion. We agree with the authors’ conclusion that
urther work in a larger SLE population is war-
anted to assess the scale of the problem and to
ove toward therapy.
eprint requests and correspondence: Dr. Dudley J. Pen-
ell, Cardiovascular Magnetic Resonance Unit, Royal
rompton Hospital, Sydney Street, London SW3 6NP,SX (7). United Kingdom. E-mail: d.pennell@imperial.ac.uk.1
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